Results 1 to 10 of about 3,651 (206)
Antidepressant Effect of an Orally Administered Dipeptide Mimetic of the Brain-Derived Neurotrophic Factor. [PDF]
Acta Naturae, 2018 Involvement of BDNF in the regulation of neuroplasticity and neurogenesis in the hippocampus, impairment of which underlies the pathophysiology of depression, makes this endogenous protein a promising object for the development of new-generation antidepressants with a neurophysiologically based mechanism of action.
Povarnina PY +3 more
europepmc +5 more sources
Biomolecules, 2021 A mimetic of the BDNF loop 4, bis (N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, named GSB-106, was designed and synthesized in our scientific group. The compound activated TrkB, MAPK/ERK, PI3K/AKT, and PLCγ in in vitro experiments.
Tatiana A Gudasheva +2 more
exaly +3 more sources
Pharmacokinetics of dipeptide mimetic BDNF GSB-106 in rats
Фармакокинетика и Фармакодинамика, 2019 Pharmacokinetics of the GSB-106 in variety of administration ways in rats was studied. After single oral administration the test substance was determined for 4 h in the blood plasma. Half-life was 0.65 h.
V. P. Zherdev +7 more
doaj +2 more sources
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk [PDF]
Pharmaceuticals, 2022 Neurotrophins are considered as an attractive target for the development of antidepressants with a novel mechanism of action. Previously, the dimeric dipeptide mimetics of individual loops of nerve growth factor, NGF (GK-6, loop 1; GK-2, loop 4) and ...
Armen G. Mezhlumyan +6 more
doaj +2 more sources
Synthesis of 1,2,4-oxadiazole-linked Orthogonally Urethane-protected Dipeptide Mimetics [PDF]
Tetrahedron Letters, 2008 The synthesis of a new class of 1,2,4-oxadiazole-linked orthogonally urethane-protected dipeptide mimetics is described. The protocol employs a reaction between an N-protected amino acyl fluoride and an amino acid-derived amidoxime.
Hosahalli, P.H. +2 more
core +3 more sources
Фармакокинетика и Фармакодинамика, 2022 Background. A dimeric dipeptide mimetic of the brain-derived neurotrophic factor loop 4, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide (GSB-106), which activates TrkB, PI3K/AKT, MAPK/ERK and PLC-γ1 was created at the V. V.
P. Yu. Povarnina +3 more
doaj +1 more source
Фармакокинетика и Фармакодинамика, 2023 The interaction of the neurotrophin BDNF dipeptide mimetic, compound GSB-106, with the tyrosine kinase TrkB receptor specific for the fullsized neurotrophin was studied using surface plasmon resonance.
A. V. Tarasiuk +4 more
doaj +1 more source
Communications Biology, 2023 The implication of reduced proteasomal function in neurodegenerative diseases combined with studies showing the protective effects of increasing proteasome activity in animal models highlight the need to understand the capacity for proteasome activation ...
Janelle J. Y. Chuah +2 more
doaj +1 more source
The pharmacokinetics of the injectable dosage form of GK-2 in rabbits
Фармакокинетика и Фармакодинамика, 2020 The pharmacokinetics of the nerve growth factor mimetic GK-2 (dimeric dipeptide mimetic of the 4-th loop NGF, a derivative of fluoro-substituted 5-[2-(5-fluoropyrid-3-yl) -ethyl)]-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole) in rabbits after a
R. V. Shevchenko +6 more
doaj +1 more source
Фармакокинетика и Фармакодинамика, 2023 Article describes results of study of antitumor and antimetastatic action of dipeptide mimetic of the nerve growth factor amide N-monosuccinyl-L-glutamyl-L-lysine (compound GK-1) in comparison with gemcitabine. Two injections of gemcitabine in total dose
L. P. Kovalenko +3 more
doaj +1 more source